Back to Authors

Ben‐Horin, Shomron

https://orcid.org/0000-0002-3984-4580

Mayo Clinic

Tel Aviv University

Citations 3

P57 Efficacy of risankizumab versus ustekinumab by disease duration in moderate-to-severe crohn’s disease: phase 3 SEQUENCE post-hoc analysis
Peyrin-Biroulet, Laurent, Ben‐Horin, Shomron, Ha, Christina , Aponte, Fernando, Kligys, Kristina, Zambrano, Javier , Anschutz, Toni , Garrison, Andrew, Peyrin‐Biroulet, Laurent , Ben‐Horin, Shomron , Siegmund, Britta , Colombel, Jean‐Frédéric

Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A123.2-A124

10.1136/gutjnl-2025-bsg.193 Get It

The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD)
Azhari, Hassan, King, James A. , Mak, Joyce W.Y., Ben‐Horin, Shomron , Loftus, Edward V. , Burisch, Johan , Lakatos, Péter L. , Padilla, Francisco Javier Bosques, Underwood, Fox E., Kaplan, Gilaad G , Loftus, Edward V , King, James , Lakatos, Peter L , Coward, Stephanie B. , Windsor, Joseph W. , Ma, Christopher , Shah, Shailja C. , Ng, Siew C. , Mak, Joyce Wing Yan , Kotze, Paulo Gustavo , Lees, Charlie W. , Gearry, Richard B. , Calvet, Xavier , Kaplan, Gilaad G.

American Journal of Gastroenterology | June 2, 2022 | Volume: 117 | Issue: 9 | Pages: 1419-1427

10.14309/ajg.0000000000001843 Get It

INTRODUCTION: Peptic ulcer disease (PUD) is a common cause of hospitalization worldwide. We assessed temporal trends in hospitalization for PUD in 36 Organisation for Economic Co-operation and Development (OECD) countries since the turn of the 21st century. METHODS: The OECD database contains data on PUD-related hospital discharges and mortality for 36 countries between 2000 and 2019. Hospitalization rates for PUD were expressed as annual rates per 100,000 persons. Joinpoint regression models were used to calculate the average annual percent change (AAPC) with 95% confidence intervals (CIs) for each country, which were pooled using meta-analyses. The incidence of PUD was forecasted to 2021 using autoregressive integrated moving average and Poisson regression models. RESULTS: The overall median hospitalization rate was 42.4 with an interquartile range of 29.7–60.6 per 100,000 person-years. On average, hospitalization rates (AAPC = −3.9%; 95% CI: −4.4, −3.3) and morality rates (AAPC = −4.7%; 95% CI: −5.6, −3.8) for PUD have decreased from 2000 to 2019 globally. The forecasted incidence of PUD hospitalizations in 2021 ranged from 3.5 per 100,000 in Mexico to 92.1 per 100,000 in Lithuania. Across 36 countries in the OECD, 329,000 people are estimated to be hospitalized for PUD in 2021. DISCUSSION: PUD remains an important cause of hospitalization worldwide. Reassuringly, hospitalizations and mortality for PUD have consistently been falling in OECD countries in North America, Latin America, Europe, Asia, and Oceania. Identifying underlying factors driving these trends is essential to sustaining this downward momentum.
Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease
Yung, Diana E., Horesh, Nir , Ben‐Horin, Shomron , Eliakim, Rami, Koulaouzidis, Anastasios , Lightner, Amy L. , Kopylov, Uri

Inflammatory Bowel Diseases | May 17, 2018 | Volume: 24 | Issue: 11 | Pages: 2327-2338

10.1093/ibd/izy156 Get It